Kevin Kalinsky
Director, Division of Medical Oncology · Emory University School of Medicine
Credentials: · · · · · · ·
History
Research
Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer
New England Journal of Medicine · 2021 · 1,378 citations
21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer
New England Journal of Medicine · 2021 · First of 34 authors · 751 citations
Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer
New England Journal of Medicine · 2019 · Last of 19 authors · 702 citations
50 papers
36 papers
30 papers
29 papers
22 papers
20 papers
- MM
19 papers
19 papers
Grants
- 2023–2028
Breast Cancer Brain Metastasis Therapy by Focused Ultrasound-Guided Control of HER2 CAR T Cells
National Cancer Institute · R01
PI · $1.3M · Georgia Institute of Technology
- 2016–2019
National Cancer Institute · R03
Contact PI · $160K · Columbia University Health Sciences
- 2014–2018
Pre-Surgical Trial of Metformin and Atorvastatin in Operable Breast Cancer
National Cancer Institute · R03
Contact PI · $149.6K · Columbia University Health Sciences
Clinical trials
- 2024–2027
ProAgio in Combination With Gemcitabine in Patients With Metastatic Triple Negative Breast Cancer
Principal investigator · Recruiting · Phase 1, Phase 2
ProDa BioTech, LLC
- 2016–2020
ACY-1215 + Nab-paclitaxel in Metastatic Breast Cancer
Principal investigator · Completed · Phase 1
Columbia University
- 2012–2019
Study of Propranolol in Newly Diagnosed Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy
Principal investigator · Completed · Phase 2
Columbia University
- 2012–2016
Study of Erlotinib and Metformin in Triple Negative Breast Cancer
Principal investigator · Completed · Phase 1
Columbia University